See more : Zhongjin Irradiation Incorporated Company (300962.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Anixa Biosciences, Inc. (ANIX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Anixa Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Solar Industries India Limited (SOLARINDS.NS) Income Statement Analysis – Financial Results
- Sierra Lake Acquisition Corp. (SIERU) Income Statement Analysis – Financial Results
- Mercato Partners Acquisition Corporation (MPRAU) Income Statement Analysis – Financial Results
- Mutual-Tek Industries Co., Ltd. (6407.TWO) Income Statement Analysis – Financial Results
- OBI Pharma, Inc. (4174.TWO) Income Statement Analysis – Financial Results
Anixa Biosciences, Inc. (ANIX)
About Anixa Biosciences, Inc.
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 210.00K | 2.47B | 512.50K | 0.00 | 250.00K | 1.11M | 362.50K | 300.00K | 9.26M | 3.67M | 388.85K | 940.01K | 1.00M | 730.68K | 1.06M | 2.06M | 486.85K | 508.65K | 439.79K | 494.46K | 244.22K | 5.19M | 1.69M | 1.47M | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 300.00K |
| Cost of Revenue | 161.00K | 42.00K | 385.00K | 90.16K | 166.25K | 768.41K | 104.56K | 217.42K | 3.65M | 1.99M | 316.66K | 3.87K | 34.08K | 82.31K | 65.69K | 95.59K | 160.36K | 156.45K | 719.63K | 176.11K | 175.94K | 1.87M | 697.64K | 463.63K | -300.00K | -300.00K | -300.00K | -100.00K | -100.00K | -100.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 49.00K | 2.47B | 127.50K | -90.16K | 83.75K | 344.09K | 257.94K | 82.58K | 5.61M | 1.68M | 72.19K | 936.14K | 969.11K | 648.37K | 990.11K | 1.97M | 326.49K | 352.21K | -279.84K | 318.35K | 68.28K | 3.32M | 993.13K | 1.01M | 400.00K | 400.00K | 400.00K | 200.00K | 200.00K | 200.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 300.00K |
| Gross Profit Ratio | 23.33% | 100.00% | 24.88% | 0.00% | 33.50% | 30.93% | 71.16% | 27.53% | 60.58% | 45.79% | 18.57% | 99.59% | 96.60% | 88.74% | 93.78% | 95.37% | 67.06% | 69.24% | -63.63% | 64.38% | 27.96% | 63.93% | 58.74% | 68.50% | 400.00% | 400.00% | 400.00% | 200.00% | 200.00% | 200.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 4.77M | 6.70M | 6.19M | 4.38M | 5.47M | 6.81M | 1.60M | 1.56M | 711.39K | 1.19M | 0.00 | 2.21M | 3.12M | 3.01M | 4.12M | 4.13M | 3.40M | 4.61M | 2.27M | 2.16M | 1.81M | 1.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.90M | 2.40M | 2.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.29M | 7.17M | 7.07M | 5.60M | 5.66M | 6.91M | 4.41M | 2.71M | 5.51M | 6.41M | 7.99M | 2.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.29M | 7.17M | 7.07M | 5.60M | 5.66M | 6.91M | 4.41M | 2.71M | 5.51M | 6.41M | 7.99M | 2.86M | 2.87M | 2.89M | 4.19M | 3.83M | 2.41M | 3.37M | 1.92M | 1.52M | 1.38M | 2.18M | 4.60M | 5.83M | 8.30M | 7.20M | 6.40M | 2.20M | 1.00M | 1.00M | 2.90M | 2.00M | 1.50M | 1.40M | 1.20M | 1.30M | 1.30M | 1.90M | 2.00M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 418.75K | 0.00 | -13.10K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 47.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.06M | 13.88M | 13.26M | 9.98M | 11.56M | 14.05M | 6.33M | 4.59M | 6.55M | 6.72M | 7.99M | 5.07M | 6.00M | 5.90M | 8.31M | 7.96M | 5.53M | 7.98M | 4.19M | 3.68M | 3.19M | 6.62M | 4.60M | 6.09M | 8.60M | 7.50M | 6.70M | 6.20M | 3.50M | 3.80M | 2.90M | 2.00M | 1.50M | 1.50M | 1.30M | 1.40M | 1.40M | 1.90M | 2.00M |
| Cost & Expenses | 11.22M | 13.88M | 13.65M | 9.98M | 11.72M | 14.82M | 6.44M | 4.81M | 10.20M | 8.71M | 8.31M | 5.07M | 6.03M | 5.98M | 8.38M | 8.05M | 5.69M | 8.14M | 4.91M | 3.86M | 3.36M | 8.50M | 5.30M | 6.56M | 8.30M | 7.20M | 6.40M | 6.10M | 3.40M | 3.70M | 2.90M | 2.00M | 1.50M | 1.50M | 1.30M | 1.40M | 1.40M | 1.90M | 2.00M |
| Interest Income | 1.08M | 104.00K | 2.32K | 33.92K | 71.35K | 45.97K | 19.44K | 12.53K | 17.62K | 8.60K | 125.00 | 3.46K | 2.52K | 4.88K | 20.81K | 37.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 104.00K | 322.00 | 0.00 | 0.00 | 0.00 | 500.46K | 519.95K | 451.91K | 1.26M | 1.11M | 7.66K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 46.00K | 42.00K | 59.86K | 90.16K | 466.31K | 343.73K | 368.51K | 358.63K | 337.81K | 314.45K | 125.00 | 7.23K | 7.98K | 8.36K | 10.61K | 10.67K | 9.89K | 15.07K | 14.71K | 17.00K | 33.08K | 86.47K | 166.50K | 261.80K | 300.00K | 300.00K | 300.00K | 100.00K | 100.00K | 100.00K | -200.00K | -200.00K | -200.00K | 100.00K | 100.00K | 100.00K | 100.00K | 0.00 | 0.00 |
| EBITDA | -10.97M | -13.73M | -13.08M | -10.00M | -11.00M | -13.36M | -4.14M | -4.14M | -601.85K | -8.03M | -8.97M | -4.24M | -6.77M | -5.25M | -7.32M | -5.98M | -5.45M | -7.61M | -4.45M | -3.35M | -3.09M | -3.22M | -3.44M | -4.82M | -7.90M | -6.80M | -6.00M | -5.90M | -3.20M | -3.50M | -3.00M | -2.10M | -1.60M | -1.30M | -1.10M | -1.20M | -1.20M | -1.80M | -1.70M |
| EBITDA Ratio | -5,221.43% | -0.56% | -2,552.44% | 0.00% | -4,234.48% | -1,148.71% | -1,569.00% | -1,379.28% | -6.37% | -128.73% | -2,036.14% | -439.47% | -500.18% | -726.46% | 178.05% | -296.14% | -1,065.76% | -1,496.61% | -1,012.10% | -677.10% | -1,263.61% | -7.74% | -203.32% | -327.67% | -7,600.00% | -6,900.00% | -6,600.00% | -6,500.00% | -3,600.00% | -3,700.00% | -3,000.00% | -2,100.00% | -1,600.00% | -1,600.00% | -1,300.00% | -1,300.00% | -1,200.00% | -1,800.00% | -566.67% |
| Operating Income | -11.01M | -13.88M | -13.14M | -9.98M | -11.47M | -14.29M | -6.08M | -4.51M | -944.76K | -5.04M | -7.92M | -4.13M | -5.03M | -5.25M | -7.32M | -5.99M | -5.49M | -7.63M | -4.47M | -3.36M | -3.12M | -3.31M | -3.60M | -5.09M | -8.20M | -7.10M | -6.30M | -6.00M | -3.30M | -3.60M | -2.80M | -1.90M | -1.40M | -1.40M | -1.20M | -1.30M | -1.30M | -1.80M | -1.70M |
| Operating Income Ratio | -5,243.33% | -0.56% | -2,563.06% | 0.00% | -4,588.50% | -1,284.41% | -1,676.02% | -1,503.00% | -10.21% | -137.54% | -2,036.17% | -439.84% | -501.23% | -718.27% | -693.35% | -290.31% | -1,128.14% | -1,499.58% | -1,015.44% | -680.54% | -1,277.15% | -63.79% | -213.17% | -345.46% | -8,200.00% | -7,100.00% | -6,300.00% | -6,000.00% | -3,300.00% | -3,600.00% | -2,800.00% | -1,900.00% | -1,400.00% | -1,400.00% | -1,200.00% | -1,300.00% | -1,300.00% | -1,800.00% | -566.67% |
| Total Other Income/Expenses | 1.08M | 104.00K | 7.69K | -114.16K | 71.35K | 45.97K | 1.07M | -507.42K | -434.28K | -4.56M | -2.16M | -118.24K | -1.75M | 73.09K | -9.17M | 167.91K | 34.15K | 26.72K | 14.51K | 4.33K | 0.00 | -2.82M | 0.00 | 0.00 | -300.00K | 100.00K | 600.00K | 600.00K | 400.00K | 200.00K | 200.00K | 200.00K | 200.00K | 300.00K | 200.00K | 100.00K | 0.00 | 1.80M | 1.70M |
| Income Before Tax | -9.93M | -13.77M | -13.13M | -10.09M | -11.82M | -14.24M | -5.01M | -5.02M | -1.38M | -9.61M | -10.08M | -4.25M | -6.78M | -5.18M | -16.49M | -5.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -6.13M | 0.00 | 0.00 | -8.50M | -7.00M | -5.70M | -5.40M | -2.90M | -3.40M | -2.60M | -1.70M | -1.20M | -1.10M | -1.00M | -1.20M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -4,728.57% | -0.56% | -2,561.55% | 0.00% | -4,727.46% | -1,280.28% | -1,381.79% | -1,672.14% | -14.90% | -261.94% | -2,592.28% | -452.42% | -675.65% | -708.27% | -1,561.76% | -282.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -118.18% | 0.00% | 0.00% | -8,500.00% | -7,000.00% | -5,700.00% | -5,400.00% | -2,900.00% | -3,400.00% | -2,600.00% | -1,700.00% | -1,200.00% | -1,100.00% | -1,000.00% | -1,200.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -280.00K | -181.29K | 40.15K | 175.80K | 289.95K | 500.46K | 12.53K | 17.62K | 1.26M | 1.11M | 430.00 | 600.00K | -73.09K | 9.17M | -167.91K | 259.65K | -26.72K | -14.51K | -4.33K | -4.67K | -23.51K | -32.28K | -120.98K | 300.00K | 0.00 | -500.00K | -600.00K | -300.00K | -200.00K | 200.00K | 100.00K | 100.00K | -300.00K | -100.00K | 0.00 | 100.00K | 1.80M | 1.70M |
| Net Income | -9.81M | -13.49M | -12.95M | -10.13M | -11.99M | -14.00M | -5.01M | -5.02M | -1.38M | -9.61M | -10.08M | -4.25M | -7.38M | -5.18M | -16.49M | -5.82M | -5.46M | -7.60M | -4.45M | -3.36M | -3.11M | -3.29M | -3.57M | -4.96M | -8.50M | -7.10M | -5.80M | -5.40M | -3.00M | -3.40M | -2.80M | -1.80M | -1.30M | -1.10M | -1.10M | -1.30M | -1.40M | -1.80M | -1.70M |
| Net Income Ratio | -4,671.90% | -0.55% | -2,526.17% | 0.00% | -4,797.78% | -1,258.07% | -1,381.79% | -1,672.14% | -14.90% | -261.94% | -2,592.28% | -452.42% | -735.46% | -708.27% | -1,561.76% | -282.17% | -1,121.12% | -1,494.33% | -1,012.14% | -679.66% | -1,275.24% | -63.34% | -211.26% | -337.24% | -8,500.00% | -7,100.00% | -5,800.00% | -5,400.00% | -3,000.00% | -3,400.00% | -2,800.00% | -1,800.00% | -1,300.00% | -1,100.00% | -1,100.00% | -1,300.00% | -1,400.00% | -1,800.00% | -566.67% |
| EPS | -0.32 | -0.44 | -0.45 | -0.46 | -0.61 | -0.79 | -0.41 | -0.57 | -0.14 | -1.00 | -1.17 | -0.53 | -1.01 | -0.79 | -2.70 | -1.02 | -1.20 | -1.81 | -1.14 | -0.92 | -0.94 | -1.10 | -1.26 | -1.81 | -3.29 | -2.79 | -2.29 | -2.24 | -1.35 | -1.59 | -1.37 | -0.91 | -0.68 | -0.68 | -0.68 | -0.68 | -0.91 | -1.14 | -1.14 |
| EPS Diluted | -0.32 | -0.44 | -0.45 | -0.46 | -0.61 | -0.79 | -0.41 | -0.57 | -0.14 | -1.00 | -1.17 | -0.53 | -1.01 | -0.79 | -2.70 | -1.02 | -1.20 | -1.81 | -1.14 | -0.92 | -0.94 | -1.10 | -1.26 | -1.81 | -3.16 | -2.69 | -2.29 | -2.17 | -1.30 | -1.59 | -1.37 | -0.91 | -0.68 | -0.68 | -0.68 | -0.68 | -0.91 | -1.14 | -1.14 |
| Weighted Avg Shares Out | 30.98M | 30.37M | 28.58M | 22.23M | 19.79M | 17.62M | 12.20M | 8.74M | 9.63M | 9.57M | 8.64M | 7.98M | 7.33M | 6.53M | 6.10M | 5.69M | 4.55M | 4.19M | 3.89M | 3.65M | 3.30M | 2.99M | 2.84M | 2.74M | 2.58M | 2.54M | 2.53M | 2.41M | 2.22M | 2.13M | 2.05M | 1.98M | 1.90M | 1.61M | 1.61M | 1.90M | 1.54M | 1.58M | 1.49M |
| Weighted Avg Shares Out (Dil) | 30.98M | 30.37M | 28.58M | 22.23M | 19.79M | 17.62M | 12.20M | 8.74M | 9.63M | 9.57M | 8.64M | 7.98M | 7.33M | 6.53M | 6.10M | 5.69M | 4.55M | 4.19M | 3.89M | 3.65M | 3.30M | 2.99M | 2.84M | 2.74M | 2.69M | 2.64M | 2.53M | 2.49M | 2.31M | 2.13M | 2.05M | 1.98M | 1.90M | 1.61M | 1.61M | 1.90M | 1.54M | 1.58M | 1.49M |
Bay Area search for coronavirus drugs extends far beyond remdesivir
Stanford, Kaiser and others are investigating other drugs that could be repurposed to fight COVID-19. A Silicon Valley company wants to find a new treatment.
The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 23.) Arcutis Biotherapeutics...
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) Biomerica, Inc. (NASDAQ...
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ...
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo...
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) Bicycle Therapeutics...
The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 9.) Arcutis...
Top Ranked Momentum Stocks to Buy for February 11th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, February 11th.
The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 13.) Arvinas Inc (NASDAQ: ARVN ) Baxter International ...
Source: https://incomestatements.info
Category: Stock Reports